Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7591584 | 0.80 | KMT2A (0.49) | KMT2AMEN1L3MBTL1CES2CES1 | |
| SCHEMBL26748191 | 0.79 | P2RX7 (0.42) | KMT2AMEN1CES1SMN1; SMN2 | |
| SCHEMBL5778478 | 0.79 | P4HTM (0.52) | KMT2AMEN1L3MBTL1LMNAP4HTM | |
| SCHEMBL133554 | 0.78 | KMT2A (0.53) | KMT2ALMNATDP1ALDH1A1MAPT | |
| SCHEMBL19309377 | 0.78 | KMT2A (0.53) | KMT2ALMNATDP1ALDH1A1MAPT | |
| SCHEMBL9266536 | 0.77 | KDM4E (0.46) | LMNANAPRTKDM4EGAATDP1 | |
| SCHEMBL1963105 | 0.77 | NPC1 (0.51) | KMT2AMEN1L3MBTL1LMNAKDM4E | |
| SCHEMBL5279917 | 0.76 | DPP4 (0.39) | KMT2A | |
| SCHEMBL17478874 | 0.75 | KMT2A (0.54) | KMT2AMEN1L3MBTL1CES2CES1 | |
| 2-Aminopyridine SCHEMBL1205100 | 0.75 | NOS3 (0.48) | KMT2AMEN1L3MBTL1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12625144-B2 | Chemoselective sensitivity booster for tagging a peptide, peptide conjugate, or similar reactive molecule | Indian Institute Of Science Education And Research Bhopal (IN) | 2026-05-12 | — | — | US | claimed |
| US-20220299521-A1 | CHEMOSELECTIVE SENSITIVITY BOOSTER FOR TAGGING A PEPTIDE, PEPTIDE CONJUGATE, OR SIMILAR REACTIVE MOLECULE | Indian Institute Of Science Education And Research Bhopal (IN) | 2022-09-22 | — | — | US | claimed |
| WO-2020245843-A1 | CHEMOSELECTIVE SENSITIVITY BOOSTER FOR TAGGING A PEPTIDE, PEPTIDE CONJUGATE, OR SIMILAR REACTIVE MOLECULE | Indian Institute Of Science Education And Research Bhopal (IN) | 2020-12-10 | — | — | WO | claimed |
| US-20120107859-A1 | METHODS FOR EARLY DETECTION OF BLOOD DISORDERS | UVIC INDUSTRY PARTNERSHIPS INC. (CA) | 2012-05-03 | — | — | US | claimed |
| US-12625144-B2 | Chemoselective sensitivity booster for tagging a peptide, peptide conjugate, or similar reactive molecule | Indian Institute Of Science Education And Research Bhopal (IN) | 2026-05-12 | — | — | US | disclosed |
| US-20230339958-A1 | NON-HYDRATED KETONE INHIBITORS OF NAV1.7 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339958-A1 | NON-HYDRATED KETONE INHIBITORS OF NAV1.7 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20220299521-A1 | CHEMOSELECTIVE SENSITIVITY BOOSTER FOR TAGGING A PEPTIDE, PEPTIDE CONJUGATE, OR SIMILAR REACTIVE MOLECULE | Indian Institute Of Science Education And Research Bhopal (IN) | 2022-09-22 | — | — | US | disclosed |
| US-11059858-B2 | Difluoroketamide derivatives as HtrA1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11059858-B2 | Difluoroketamide derivatives as HtrA1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11014963-B2 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-11014963-B2 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-05-25 | — | — | US | disclosed |
| WO-2018036942-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-01 | — | — | WO | disclosed |
| WO-2018036942-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-01 | — | — | WO | disclosed |
| US-20140315797-A1 | Novel N-Terminally Modified Insulin Derivatives | NOVO NORDISK A/S (DK) | 2014-10-23 | — | — | US | disclosed |
| EP-2451966-A1 | METHODS FOR EARLY DETECTION OF BLOOD DISORDERS | UVic Industry Partnerships Inc. (CA) | 2012-05-16 | — | — | EP | disclosed |
| US-20120107859-A1 | METHODS FOR EARLY DETECTION OF BLOOD DISORDERS | UVIC INDUSTRY PARTNERSHIPS INC. (CA) | 2012-05-03 | — | — | US | disclosed |
| WO-2011003182-A1 | METHODS FOR EARLY DETECTION OF BLOOD DISORDERS | UNIVERSITY OF VICTORIA INNOVATION AND DEVELOPMENT CORPORATION (CA) | 2011-01-13 | — | — | WO | disclosed |
| US-4678800-A | INHIBITORS OF ANGIOTENSIN-CONVERTING ENZYME | CIBA-GEIGY CORPORATION (US) | 1987-07-07 | — | — | US | disclosed |
| US-4401594-A | PROTEOLYTIC ENZYME INHIBIJTORS; CARDIOVASCULAR AND MUSCULAR DISORDERS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1983-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059858-B2 | Difluoroketamide derivatives as HtrA1 inhibitors | HTRA1, HTR1A, HTR1E | KMT2A 541/4885MEN1 995/4885L3MBTL1 2301/4885 |
| US-20140315797-A1 | Novel N-Terminally Modified Insulin Derivatives | IAPP, INSR, IRS1 | KMT2A 3876/4885MEN1 115/4885L3MBTL1 4437/4885 |
| US-20220299521-A1 | CHEMOSELECTIVE SENSITIVITY BOOSTER FOR TAGGING A PEPTIDE, PEPTIDE CONJUGATE, OR SIMILAR REACTIVE MOLECULE | PTMS, PA2G4, MAX | KMT2A 3541/4885MEN1 2481/4885L3MBTL1 3442/4885 |
| US-11014963-B2 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | HTRA1, HTR3E, HTR1F | KMT2A 1252/4885MEN1 1631/4885L3MBTL1 1703/4885 |
| US-20230339958-A1 | NON-HYDRATED KETONE INHIBITORS OF NAV1.7 FOR THE TREATMENT OF PAIN | SCN7A, SCN10A, HCN3 | KMT2A 1869/4885MEN1 3901/4885L3MBTL1 3972/4885 |
| US-12625144-B2 | Chemoselective sensitivity booster for tagging a peptide, peptide conjugate, or similar reactive molecule | DPYSL3, CD2BP2, PTMS | KMT2A 4121/4885MEN1 4377/4885L3MBTL1 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.